Upsher-Smith increases shareholding in Proximagen

Proximagen, a company focused on diseases of the central nervous system, has announced that pharmaceutical company Upsher-Smith Laboratories has increased its shareholding in the company from 6.4 to 7.6 per cent with the acquisition of 700,000 ordinary shares in the company.

Upsher-Smith is now directly interested in 4,365,700 ordinary shares in Proximagen.